They found that mutant p53 aggregates hindered the apoptotic function of wild-type p53 in recipient cells, and p53 aggregation inhibitors restored cell apoptosis in tumor organoids derived from patients carrying p53 aggregates, which is an appropriate p53 function (Iwahashi et al., 2022). Here, TP53 is linked to neoplasm.